BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.